One year after the appearance of the virus, the AstraZeneca vaccine is one of the first unveiled with that of the American laboratory Moderna and that of the American and German laboratories Pfizer / BioNTech.
The first vaccine validated by independent scientists
According to the British scientific journal The Lancet, the vaccine developed by AstraZeneca and the British University of Oxford is “ safe and efficient “To prevent Covid-19, allowing” protect against severe forms of illness and hospitalization According to the review. While the scientific community had expressed doubts after a dosage error during the experiments, the scientific journal confirms that the vaccine is 70% effective on average, as AstraZeneca reported on November 23.
Many independent scientists were thus able to examine in detail the publication of the results of the study, with the figures given by AstraZeneca during the tests. The vaccine study was carried out on 11,636 British, South African and Brazilian volunteers. The group of volunteers was split into two, one receiving the vaccine and the other a placebo. The effectiveness of the vaccine depends on the number of people catching the coronavirus in the vaccinated group compared to the placebo group. Two weeks later, 131 cases of covid were detected: 30 in the vaccinated group out of 5,807 volunteers and 101 in the placebo group with 5,829 volunteers. The figures therefore show an efficiency of 70%.
An “additional study” after a dosage error
Two protocols were tested during the trial: 1367 British volunteers received a half dose. A month later, a second full dose was injected. Result, the efficiency is 90%. A percentage that goes down to 62% for other people vaccinated with two complete injections one month apart as a protocol. According to the laboratory, this would be a dosage error. This is why a “ additional study Has been requested in order to verify the results. Out of a total of 23,754 volunteers who participated in the various trials, only three cases with “ serious side effects possibly related At the injection were identified: a vaccinated patient, a second on placebo and a third whose group is still unknown. According to the American laboratory, “ these three participants are cured or in the process of being cured and continue to be part of the trial “. ” We have started submitting the data to regulatory authorities around the world for rapid clearance and our production lines are up and running »Said Pascal Soriot, CEO of AstraZeneca.
